Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

CCCC
C4 Therapeutics, Inc.
stock NASDAQ

At Close
May 9, 2025 3:59:55 PM EDT
1.45USD-5.844%(-0.09)1,169,516
0.00Bid   0.00Ask   0.00Spread
Pre-market
May 8, 2025 9:09:30 AM EDT
1.53USD-0.649%(-0.01)0
After-hours
May 9, 2025 4:35:30 PM EDT
1.53USD+5.517%(+0.08)379
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 10, 2022
07:36AM EST  C4 Therapeutics Announces 2022 Targets   Benzinga
07:00AM EST  Initial Phase 1 Data for CFT7455, a Novel IKZF1/3 Degrader, Expected in 1H 2022   GlobeNewswire Inc
Jan 3, 2022
07:00AM EST  C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced that the Company will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 10:30 a.m. EST.   GlobeNewswire Inc
Dec 17, 2021
08:12AM EST  C4 Therapeutics Reports Will Be Added To NASDAQ Biotech Index, Effective Dec. 20, 2021   Benzinga
08:00AM EST  C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced its inclusion on the NASDAQ Biotechnology Index (Nasdaq: NBI), effective on December 20, 2021.   GlobeNewswire Inc
Nov 23, 2021
10:17AM EST  Benzinga's Top Ratings Upgrades, Downgrades For November 23, 2021   Benzinga
06:55AM EST  B of A Securities Initiates Coverage On C4 Therapeutics with Buy Rating, Announces Price Target of $54   Benzinga
Nov 10, 2021
04:42PM EST  C4 Therapeutics Q3 EPS $(0.51) Beats $(0.59) Estimate, Sales $8.50M Beat $7.61M Estimate   Benzinga
04:01PM EST  Phase 1/2 study of CFT7455, a Novel IKZF1/3 Degrader, Progressing with Data Expected in 2022; Trial-in-Progress Poster Accepted for Presentation at 63rd ASH Annual Meeting   GlobeNewswire Inc
Oct 14, 2021
11:18AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2021   Benzinga
07:39AM EDT  SVB Leerink Initiates Coverage On C4 Therapeutics with Outperform Rating, Announces Price Target of $67   Benzinga
Sep 30, 2021
11:04AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021   Benzinga
04:51AM EDT  Stifel Initiates Coverage On C4 Therapeutics with Hold Rating, Announces Price Target of $45   Benzinga
Sep 22, 2021
07:45AM EDT  The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs   Benzinga
Sep 14, 2021
07:50AM EDT  The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout   Benzinga
Sep 10, 2021
08:00AM EDT  The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test   Benzinga
Aug 12, 2021
08:09AM EDT  The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma   Benzinga
06:39AM EDT  C4 Therapeutics Multiple Myeloma Candidate Scores FDA Orphan Drug Tag   Benzinga
Aug 11, 2021
04:23PM EDT  C4 Therapeutics Q2 EPS $(0.51)   Benzinga
04:22PM EDT  C4 Therapeutics Announces FDA Orphan Drug Designation for CFT7455 for the Treatment of Multiple Myeloma   Benzinga
04:02PM EDT  Dosed First Patient in Phase 1/2 Clinical Trial of CFT7455, a novel IKZF1/3 Degrader, in Hematologic Malignancies; Data Expected in 2022   GlobeNewswire Inc
04:01PM EDT  C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to CFT7455 for the treatment of multiple myeloma.   GlobeNewswire Inc
Jun 24, 2021
10:07AM EDT  Brookline Capital Initiates Coverage On C4 Therapeutics with Buy Rating, Announces Price Target of $54   Benzinga
Jun 21, 2021
04:01PM EDT  C4 Therapeutics Announces Closing of Public Offering and Exercise   GlobeNewswire Inc
08:11AM EDT  C4 Therapeutics Highlights Presentation Of Pre-Clinical Data On CFT7455 For Treatment Of Hematologic Malignancies, at the 16th Annual International Conference on Malignant Lymphoma   Benzinga
08:00AM EDT  CFT7455 Demonstrated High Binding Affinity to Cereblon and Target Selectivity in Non-Hodgkins Lymphoma Cell Models, Producing Rapid and Deep Degradation of IKZF1/3 Proteins   GlobeNewswire Inc
Jun 16, 2021
07:51PM EDT  C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced the pricing of an underwritten public offering of 4,250,000 shares of its common stock at a public offering price of $37.00 per share.   GlobeNewswire Inc
Jun 15, 2021
08:07AM EDT  The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda   Benzinga
Jun 14, 2021
04:13PM EDT  C4 Therapeutics Launches Proposed Public Offering Of 4.25M Shares Of Common Stock   Benzinga
04:12PM EDT  C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced that it has launched a proposed public offering of 4,250,000 shares of its common stock.   GlobeNewswire Inc
08:01AM EDT  C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT7455, An Orally Bioavailable MonoDAC for Hematologic Malignancies   Benzinga
08:00AM EDT  C4 Therapeutics Announces First Patient Dosed in Phase 1/2   GlobeNewswire Inc
Jun 7, 2021
07:06AM EDT  C4 Therapeutics Presents Pre-clinical Data on CFT8919, A Selective Degrader of EGFR L858R, at Keystone Symposium on Targeted Protein Degradation   Benzinga
07:00AM EDT  CFT8919 Induces Tumor Regression in Pre-clinical Models Resistant to First- and Third-generation EGFR Inhibitors   GlobeNewswire Inc
Jun 4, 2021
10:03AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For June 4, 2021   Benzinga
06:09AM EDT  HC Wainwright & Co. Initiates Coverage On C4 Therapeutics with Buy Rating, Announces Price Target of $63   Benzinga
May 26, 2021
07:03AM EDT  C4 Therapeutics To Advance CFT8919, A Selective Degrader Of EGFR L858R, Into IND-Enabling Studies   Benzinga
07:00AM EDT  IND Submission for CFT8919 Anticipated mid-2022; Phase 1/2 Trial Initiation Expected by YE 2022   GlobeNewswire Inc
May 20, 2021
04:01PM EDT  C4 Therapeutics Appoints Lauren White as Chief Financial Officer   Benzinga
May 13, 2021
04:35PM EDT  C4 Therapeutics Q1 EPS $(0.49), Sales $7.40M Up From $6.80M YoY   Benzinga
04:01PM EDT  Preclinical Data for CFT7455, a novel IKZF1/3 Degrader, in Non-Hodgkin's Lymphoma Xenograft Models Accepted for Presentation at the International Conference on Malignant Lymphoma (ICML)in June   GlobeNewswire Inc
May 12, 2021
07:00AM EDT  C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced that the Company will participate in the following upcoming investor conferences:   GlobeNewswire Inc
Apr 10, 2021
03:05PM EDT  CFT7455 Demonstrated High Cereblon Binding Affinity and Rapid, Deep IKZF1/3 Degradation Enabling Activity across a Panel of Multiple Myeloma Cell Lines Including IMiD-Resistant Models   GlobeNewswire Inc
Mar 31, 2021
10:03AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2021   Benzinga
06:33AM EDT  BMO Capital Initiates Coverage On C4 Therapeutics with Outperform Rating, Announces Price Target of $55   Benzinga
Mar 11, 2021
04:05PM EST  C4 Therapeutics Reports FY20 Sales $33.195M Up From $21.381M YoY   Benzinga
04:01PM EST  Phase 1/2 Trial for Lead Candidate CFT7455, a MonoDAC Degrader Targeting IKZF1/3 for the Treatment of Hematologic Malignancies, On Track for 1H 2021 Initiation Following FDA Clearance of Investigational New Drug (IND)   GlobeNewswire Inc
Mar 10, 2021
04:41PM EST  C4 Therapeutics To Present On Discovery, Preclinical Development Of CFT7455 MonoDAC Degrader At American Association For Cancer Research Apr. 10   Benzinga
04:41PM EST  C4 Therapeutics to Present on the Discovery and Preclinical   GlobeNewswire Inc
Feb 24, 2021
07:00AM EST  C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced that the Company will participate in the following upcoming March investor conferences:   GlobeNewswire Inc
Feb 11, 2021
11:21AM EST  Stocks That Hit 52-Week Highs On Thursday   Benzinga
07:00AM EST  C4 Therapeutics to Participate in BMO BioPharma Spotlight Series   GlobeNewswire Inc
Feb 9, 2021
08:10AM EST  The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement   Benzinga
Feb 4, 2021
07:22AM EST  The Daily Biotech Pulse: Novartis COVID-19 Drug Readout, Merck And Roche Earnings, 3 IPOs   Benzinga
Feb 3, 2021
07:31AM EST  The Daily Biotech Pulse: Amgen Earnings, GSK-CureVac Vaccine Collaboration, Mallinckrodt FDA Decision   Benzinga
Jan 19, 2021
07:01AM EST  C4 Therapeutics Announces FDA Clearance Of Investigational New Drug Application For CFT7455, An Orally Bioavailable MonoDAC For Hematologic Malignancies   Benzinga
07:00AM EST  C4 Therapeutics Announces FDA Clearance of Investigational New   GlobeNewswire Inc
Jan 15, 2021
07:57AM EST  The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges   Benzinga
Jan 14, 2021
07:57AM EST  The Daily Biotech Pulse: Alexion Pauses COVID-19 Study, NantKwest Readout, Organogenesis Jumps On Guidance, Trial Updates   Benzinga
Jan 12, 2021
08:16AM EST  The Daily Biotech Pulse: GSK, Vir To Start COVID-19 Antibody Study, Novartis In-Licenses BeiGene's Cancer Drug, Earnings Preannouncements Continue   Benzinga
Jan 7, 2021
07:00AM EST  C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced that the Company will present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021 at 2:50 p.m. ET.   GlobeNewswire Inc
Jan 6, 2021
07:00AM EST  Investigational New Drug (IND) Application for Lead Candidate CFT7455, a MonoDAC targeting IKZF1/3 for the Treatment of Hematologic Malignancies, Under FDA Review; Initiation of Phase 1/2 Trial Expected in 1H 2021   GlobeNewswire Inc
Dec 23, 2020
08:31AM EST  The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut   Benzinga
Dec 17, 2020
07:00AM EST  C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively destroys disease-causing proteins through degradation, today announced that the Company will be added to the Russell 2000 and Russell 3000 Indexes as part of the Russell quarterly update, effective December 21, 2020.   GlobeNewswire Inc
Nov 25, 2020
07:35AM EST  The Daily Biotech Pulse: Revance's DAXI Regulatory Decision, Reata Slips On FDA Feedback, Liquidia Setback   Benzinga
07:00AM EST  C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively destroys disease-causing proteins through degradation, today announced that the Company will present at the Evercore ISI 3rd Annual HealthCONx on Thursday, December 3, 2020 at 8:25 a.m. ET.   GlobeNewswire Inc
Nov 19, 2020
08:17AM EST  The Daily Biotech Pulse: Aquestive's Positive FDA Meeting, Prevail Awarded Patent, Neuro-Oncology Conference Gets Underway   Benzinga
Nov 18, 2020
07:30AM EST  The Daily Biotech Pulse: Kazia Jumps On Data Readout, Clinical Hold On Cellectis' Blood Cancer Study Lifted   Benzinga
Nov 17, 2020
09:52AM EST  Stocks Trading Near 52-Week Highs Just After Open On Tuesday, Nov. 17, 2020: CAPA, FSRVU, TRTN, ATRA, BEEMW, COOP, NBACU, STKL, KLAC, DLB, PCGU, GNTX, CSV, CCCC, DAC, BHVN, DTP, ACHC, GM, QCOM, FOLD, SNX, GRWG, CHI, CHY, UPWK   Benzinga
Nov 13, 2020
07:00AM EST  C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively destroys disease-causing proteins through degradation, today announced that the Company will present at the Jefferies Virtual London Healthcare Conference on Thursday, November 19, 2020 at 8:30 a.m. ET.   GlobeNewswire Inc
Nov 12, 2020
04:08PM EST  C4 Therapeutics Q3 EPS $(17.55) Down From $(8.93) YoY, Sales $8.45M Up From $5.36M YoY   Benzinga
Nov 10, 2020
08:40AM EST  The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies   Benzinga
Oct 27, 2020
11:28AM EDT  C4 Therapeutics shares are trading higher after BMO Capital initiated coverage on the stock with an Outperform rating and a price target of $33 per share.   Benzinga
10:35AM EDT  Benzinga's Top Upgrades, Downgrades For October 27, 2020   Benzinga
06:49AM EDT  BMO Capital Initiates Coverage On C4 Therapeutics with Outperform Rating, Announces Price Target of $33   Benzinga
Oct 14, 2020
07:30AM EDT  C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins through degradation, today announced that it will present in a talk and roundtable discussion at the 3rd Annual Targeted Protein Degradation Summit on October 14 and 15.   GlobeNewswire Inc
Oct 6, 2020
04:05PM EDT  C4 Therapeutics Announces Closing of Initial Public Offering and   GlobeNewswire Inc
Oct 2, 2020
11:32AM EDT  C4 Therapeutics Shares Open For Trade At $26.60; IPO Priced At $19/Share   Benzinga
10:16AM EDT  C4 Therapeutics Shares Indicated $38 On 45K Shares   Benzinga
10:03AM EDT  C4 Therapeutics Shares Expected To Open For Quote At 10:10 a.m. EDT, Shares Expected To Open For Trade After 10:20 a.m. EDT; IPO Priced At $19/Share   Benzinga
05:35AM EDT  C4 Therapeutics Priced Upsized 9.6M Share IPO @$19/Share   Benzinga
Oct 1, 2020
10:32PM EDT  C4 Therapeutics Prices Upsized IPO Of 9.6 Mln Shares At $19/shr   RTTNews
09:59PM EDT  C4 Therapeutics Announces Pricing of an Upsized Initial Public   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC